Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials

Baricitinib is a selective Janus kinase inhibitor that has recently been approved for treating certain autoimmune disorders. This meta-analysis pooled the conflicting results from all published randomized controlled trials (RCTs) about the efficacy and safety of baricitinib in patients with systemic...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2024-02, Vol.43 (2), p.579-589
Main Authors: Amer, Basma Ehab, Afifi, Eslam, Mouffokes, Adel, Hamad, Abdullah Ashraf, Amin, Ahmed Mostafa, Abdelwahab, Omar Ahmed
Format: Article
Language:English
Subjects:
Autoimmune diseases
Azetidines - adverse effects
Azetidines - therapeutic use
Clinical trials
Enzyme inhibitors
Humans
Janus kinase
Janus Kinase Inhibitors - adverse effects
Lupus
Lupus Erythematosus, Systemic - chemically induced
Lupus Erythematosus, Systemic - drug therapy
Medicine
Medicine & Public Health
Meta-analysis
Patients
Purines
Pyrazoles
Randomized Controlled Trials as Topic
Review Article
Rheumatology
Statistics
Sulfonamides
Systemic lupus erythematosus
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Baricitinib is a selective Janus kinase inhibitor that has recently been approved for treating certain autoimmune disorders. This meta-analysis pooled the conflicting results from all published randomized controlled trials (RCTs) about the efficacy and safety of baricitinib in patients with systemic lupus erythematosus (SLE). We systemically searched four electronic databases. RCTs comparing baricitinib versus placebo were included. Our outcomes were pooled as the risk ratio (RR) in the random effects model. Our primary outcome was the proportion of patients who achieved a SLE Responder Index-4 (SRI-4) response. A total of three RCTs, comprising 1849 patients, were included. Baricitinib 4 mg was associated with a significantly higher proportion of patients who attained SRI-4 response at week 24 (RR = 1.19, 95% CI [1.05, 1.35], P  
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-023-06731-4